Citations

Clear

3030 citation(s) found for "Susan, M".

Recurrent spontaneous coronary artery dissection
Kok, Susan N., Tweet, Marysia S.

Mayo Clinic

Expert Review of Cardiovascular Therapy | January 18, 2021 | Volume: 19 | Issue: 3 | Pages: 201-210

10.1080/14779072.2021.1877538 | PMID 33455483 Get It

Preoperative Anemia Screening and Treatment: Is It Worth the Return on Investment?
Goobie, Susan M. , Warner, Matthew A.

Mayo Clinic

Anesthesia & Analgesia | January 15, 2021 | Volume: 132 | Issue: 2 | Pages: 341-343

10.1213/ane.0000000000005313 | PMID 33449557 Get It

Ultrasound-guided transversus abdominis plane block vs trigger point injections for chronic abdominal wall pain: a randomized clinical trial
Moeschler, Susan M. , Pollard, E. Morgan, Pingree, Matthew J. , Bendel, Mark A., Mauck, William D. , Watson, James C. , Eldrige, Jason S. , Loftus, Conor G., Hooten, W. Michael , Mauck, W David, Pittelkow, Thomas P.

Mayo Clinic

Pain | January 14, 2021 | Volume: 162 | Issue: 6 | Pages: 1800-1805

10.1097/j.pain.0000000000002181 | PMID 33433147 Get It

Abstract The primary aim of this randomized clinical trial is to investigate the effects of ultrasound-guided transversus abdominis plane (TAP) vs ultrasound-guided trigger point injections (TPIs) on numerical rating scale pain scores at month 3 follow-up in patients with a chronic abdominal wall pain. The primary outcome measure was the difference in mean numeric rating scale pain scores between the TAP and TPI groups at month 3 in an intent-to-treat (ITT) analysis. A total of 60 patients were randomized 1:1 to receive an ultrasound-guided TAP block (n = 30) or an ultrasound-guided TPI (n = 30). No significant group differences in baseline demographic or clinical characteristics were observed. The mean baseline pain score for the TAP and TPI groups was 5.5 and 4.7, respectively. In the ITT analysis at month 3, the between-group difference in pain scores was 1.7 (95% confidence interval, 0.3-3.0) favoring the TPI group. In a secondary per-protocol analysis, the between-group difference in pain scores was 1.8 (95% confidence interval, 0.4-3.2) favoring the TPI group. For the ITT and per-protocol analyses, the group differences in pain scores were consistent with a medium effect size. The main finding of this randomized clinical trial is that adults with chronic abdominal wall pain who received a TPI reported significantly lower pain scores at month 3 follow-up compared with patients who received a TAP block.
NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021
Altman, Jessica K. , Assi, Rita, Bachiashvili, Kimo, Fathi, Amir T. , Fedorov, Kateryna, Foran, James M. , Gojo, Ivana , Goldberg, Aaron, Hall, Aric C. , Jonas, Brian A., Levine, Matthew R., Mangan, James, Mannis, Gabriel N. , Marcucci, Guido , Moriarty, Kelsey, Ali, Moaath Mustafa, Neff, Jadee , Nejati, Reza , Olin, Rebecca L. , Patel, Anand, Percival, Mary‐Elizabeth M. , Perl, Alexander E. , Pettit, Kristen, Rao, Dinesh S. , Ravandi‐Kashani, Farhad, Schwabkey, Zaker, Shallis, Rory, Stahl, Maximilian, Stone, Richard M. , Thota, Swapna, Uy, Geoffrey L., Walker, Alison, Wang, Eunice, Awotiwon, Ajibola, Roth, Sydney L., Stehman, Katie, Strickland, Stephen A. , Przespolewski, Amanda , Strickland, Stephen Anthony , Pollyea, Daniel Aaron , Assi, Rita, Bachiashvili, Kimo, Bhatt, Vijaya Raj , Fedorov, Kateryna, Goldberg, Aaron, Jonas, Brian A., Levine, Matthew R., Mangan, James, Mims, Alice S , Moriarty, Kelsey, Ali, Moaath Mustafa, Patel, Anand, Pettit, Kristen, Schwabkey, Zaker, Shallis, Rory, Stahl, Maximilian, Thota, Swapna, Uy, Geoffrey L., Walker, Alison, Wang, Eunice, Awotiwon, Ajibola, Roth, Sydney L., Stehman, Katie

Mayo Clinic

Journal of the National Comprehensive Cancer Network | January 6, 2021 | Volume: 19 | Issue: 1 | Pages: 16-27

10.6004/jnccn.2021.0002 | PMID 33406488 Get It

The NCCN Guidelines for Acute Myeloid Leukemia (AML) provide recommendations for the diagnosis and treatment of adults with AML based on clinical trials that have led to significant improvements in treatment, or have yielded new information regarding factors with prognostic importance, and are intended to aid physicians with clinical decision-making. These NCCN Guidelines Insights focus on recent select updates to the NCCN Guidelines, including familial genetic alterations in AML, postinduction or postremission treatment strategies in low-risk acute promyelocytic leukemia or favorable-risk AML, principles surrounding the use of venetoclax-based therapies, and considerations for patients who prefer not to receive blood transfusions during treatment.
Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Daly, Mary B., Dickson, Patricia , Elkhanany, Ahmed , Friedman, Susan , Hutton, Mollie L., CGC, Khan, Seema, Klein, Catherine, Kohlmann, Wendy , CGC, Kurian, Allison W. , Laronga, Christine , Mak, Julie , LCGC, Menendez, Carolyn S. , Merajver, Sofía D. , Norquist, Barbara S., Offit, Kenneth , Pederson, Holly J. , Reiser, Gwen , CGC, Senter-Jamieson, Leigha, CGC, Shannon, Kristen M. , Shatsky, Rebecca , Visvanathan, Kala , Weitzel, Jeffrey N. , Wick, Myra , Wisinski, Kari B. , Yurgelun, Matthew B. , Darlow, Susan, Dwyer, Mary A., Norquist, Barbara M. , Weitzel, Jeffrey N , Visvanathan, Kala , Kurian, Allison W , Norquist, Barbara , Elkhanany, Ahmed , Shatsky, Rebecca , Pal, Tuya , Berry, Michael P., Buys, Saundra S. , Domchek, Susan M. , Goggins, Michael , CGC, Karlan, Beth Y. , CGC, Litton, Jennifer K. , LCGC, CGC, CGC

Mayo Clinic

Journal of the National Comprehensive Cancer Network | January 6, 2021 | Volume: 19 | Issue: 1 | Pages: 77-102

10.6004/jnccn.2021.0001 | PMID 33406487 Get It

The NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic focus primarily on assessment of pathogenic or likely pathogenic variants associated with increased risk of breast, ovarian, and pancreatic cancer and recommended approaches to genetic testing/counseling and management strategies in individuals with these pathogenic or likely pathogenic variants. This manuscript focuses on cancer risk and risk management for BRCA-related breast/ovarian cancer syndrome and Li-Fraumeni syndrome. Carriers of a BRCA1/2 pathogenic or likely pathogenic variant have an excessive risk for both breast and ovarian cancer that warrants consideration of more intensive screening and preventive strategies. There is also evidence that risks of prostate cancer and pancreatic cancer are elevated in these carriers. Li-Fraumeni syndrome is a highly penetrant cancer syndrome associated with a high lifetime risk for cancer, including soft tissue sarcomas, osteosarcomas, premenopausal breast cancer, colon cancer, gastric cancer, adrenocortical carcinoma, and brain tumors.
Association of Compensation and Educational Debt with Burnout and Perceived Impact of Debt on Women Physicians' Career and Lifestyle Choices
Moeschler, Susan M. , Larson, Allison R , Jagsi, Reshma , Silver, Julie K.

Mayo Clinic

Health Equity | January 4, 2021 | Volume: 4 | Issue: 1 | Pages: 565-570

10.1089/heq.2020.0048 Get It

“This experience changed my life”: inspiring college students to pursue careers caring for persons living with dementia
Hamilton, Gillian , Lowes, Susan , Hochstetler, Vicki, Pierson, Kristen, Volk, Kylee, Hamilton, Gillian

Mayo Clinic

Educational Gerontology | January 4, 2021 | Volume: 47 | Issue: 2 | Pages: 72-78

10.1080/03601277.2020.1864703 Get It

208. Variation in Clinical Practice and Attitudes in the Management of Fever and Neutropenia in Patients With Hematologic Malignancy: A Survey of Cancer Centers Across the United States
Barreto, Jason N. , Nagel, Jerod , Seo, Susan K. , Liu, Catherine , Aitken, Samuel L

Mayo Clinic

Open Forum Infectious Diseases | January 2, 2021 | Volume: 7 | Issue: Supplement_1 | Pages: S107-S107

10.1093/ofid/ofaa439.252 Get It

Abstract Background Fever and neutropenia (FN) is common in cancer patients after chemotherapy, and there are national guideline recommendations for FN prevention and treatment. We conducted a survey of practices across multiple US cancer centers to determine the extent to which these guidelines have been adapted. Methods US cancer centers performing 20 allogeneic hematopoietic stem cell transplantations annually were identified from the National Marrow Donor Program’s “Be the Match” directory. Antimicrobial stewardship physicians and pharmacists at each institution were identified using institutional websites, residency or fellowship program directories, and personal contacts. A survey assessing institutional practices and individual attitudes on FN management in high-risk patients was distributed via email. Duplicate responses at the hospital level were removed. Complete surveys regarding individual attitudes were assessed using a 5-point Likert scale ranging from “Strongly Agree” to “Strongly Disagree.” Results Thirty-four (23%) responses from 148 individuals were received, representing 31 of 86 hospitals (36%). 29 (94%) hospitals reported having guidelines for the management of FN. Of these, cefepime was the most commonly recommended agent for empiric treatment (26, 90%) and 16 (55%) provide guidance based on presumed site of infection. Eighteen (62%) hospitals recommend de-escalation of Gram negative therapy in certain situations, most often after being afebrile 48 – 72 hours or after neutrophil recovery (7 each, 39%). Twenty-seven (93%) hospitals recommended antibiotic prophylaxis, most often with levofloxacin (21, 78%). Of 34 respondents, attitudes were split regarding the statement “The benefit of antibiotic prophylaxis outweighs the harms in high-risk patients” (10 strongly agree or agree, 10 strongly disagree or disagree; 29% each); most agreed with the statement “I would use antibiotic prophylaxis in high-risk patients” (25, 78%). Conclusion Most cancer centers across the US have guidelines for the management of FN. While most recommend antibacterial prophylaxis, there were differences in individual perceptions regarding the risk / benefit. Significant variation exists in the approach to antibiotic de-escalation. Disclosures All Authors: No reported disclosures
Neuromuscular ultrasound competency assessment: Consensus‐based survey
Tawfik, Eman A. , Cartwright, Michael S. , Grimm, Alexander , Boon, Andrea J. , Kerasnoudis, Antonios , Preston, David C. , Axer, Hubertus , Hobson‐Webb, Lisa D., Crump, Nicholas , Inkpen, Peter, Mandeville, Ross , Sakamuri, Sarada, Shook, Steven J. , Shin, Susan , Walker, Francis O. , Crump, Nicholas , Shin, Susan , Wilder‐Smith, Einar , Alfen, Nens van , Shahrizaila, Nortina

Mayo Clinic

Muscle & Nerve | December 31, 2020 | Volume: 63 | Issue: 5 | Pages: 651-656

10.1002/mus.27163 | PMID 33382094 Get It

AbstractNeuromuscular ultrasound is a rapidly evolving specialty with direct application for patient care. Competency assessment is an essential standard needed to ensure quality for practitioners, particularly for those newly acquiring skills with the technique. Our aim was to survey experts' opinions regarding physician competency assessment of neuromuscular ultrasound and to identify minimal competency of knowledge and skills. The opinions of 18 experts were obtained through the Delphi method using two consecutive electronic surveys. A high degree of consensus was achieved on items regarding framework and the conduct of neuromuscular ultrasound assessment and the knowledge and skills that a candidate needs to attain minimal competency in neuromuscular ultrasound. In this study, a group of neuromuscular ultrasound experts developed a general framework for neuromuscular ultrasound competency assessment and recommended testable areas of knowledge and skills suitable for establishing minimal competency.
Adoption of Active Surveillance for Very Low-Risk Differentiated Thyroid Cancer in the United States: A National Survey
Pitt, Susan C. , Yang, Nan , Saucke, Megan C. , Marka, Nicholas , Long, Kristin L. , McDow, Alexandria D. , Brito, Juan P. , Roman, Benjamin R. , Brito, Juan P , Hanlon, Bret M.

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | December 29, 2020 | Volume: 106 | Issue: 4 | Pages: 1728-1737

10.1210/clinem/dgaa942 | PMID 33373458 Get It

Abstract Context Active surveillance (AS) of thyroid cancer with serial ultrasounds is a newer management option in the United States. Objective This work aimed to understand factors associated with the adoption of AS. Methods We surveyed endocrinologists and surgeons in the American Medical Association Masterfile. To estimate adoption, respondents recommended treatment for 2 hypothetical cases appropriate for AS. Established models of guideline implementation guided questionnaire development. Outcome measures included adoption of AS (nonadopters vs adopters, who respectively did not recommend or recommended AS at least once; and partial vs full adopters, who respectively recommended AS for one or both cases). Results The 464 respondents (33.3% response) demographically represented specialties that treat thyroid cancer. Nonadopters (45.7%) were significantly (P < .001) less likely than adopters to practice in academic settings, see more than 25 thyroid cancer patients/year, be aware of AS, use applicable guidelines (P = .04), know how to determine whether a patient is appropriate for AS, have resources to perform AS, or be motivated to use AS. Nonadopters were also significantly more likely to be anxious or have reservations about AS, be concerned about poor outcomes, or believe AS places a psychological burden on patients. Among adopters, partial and full adopters were similar except partial adopters were less likely to discuss AS with patients (P = .03) and more likely to be anxious (P = .04), have reservations (P = .03), and have concerns about the psychological burden (P = .009) of AS. Few respondents (3.2%) believed patients were aware of AS. Conclusion Widespread adoption of AS will require increased patient and physician awareness, interest, and evaluation of outcomes.